,NR 565 AdvANced PhARmAcology FuNdAmeNtAls – AcAdemic yeAR 2026/2027
– midteRm comPReheNsive exAmiNAtioN with veRiFied QuestioNs ANd coRRect
ANsweR RAtioNAles | | just ReleAsed .
This comprehensive practice examination covers the foundational principles of
pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacotherapeutics across
broad categories of agents used to treat common conditions encountered by the advanced
practice nurse. Topics include autonomic pharmacology, cardiovascular and renal
pharmacotherapy, endocrine agents, central nervous system medications, anti-infectives, and
special population considerations.
DOMAIN I: PHARMACOKINETICS, PHARMACODYNAMICS, AND PRESCRIBING
PRINCIPLES (Questions 1–25)
Question 1
A patient taking warfarin for atrial fibrillation is started on cimetidine for gastroesophageal reflux
disease. The nurse practitioner should anticipate which effect?
A. Decreased warfarin levels and increased INR
B. Increased warfarin levels and increased INR
C. Decreased warfarin levels and decreased INR
D. No change in warfarin levels or INR
ANsweR: B. Increased warfarin levels and increased INR
RAtioNAle: Cimetidine is a CYP450 inhibitor that inhibits the metabolism of warfarin, leading to
increased warfarin levels and increased INR. This increases the risk of bleeding. The NP should
monitor INR closely and consider alternative H2 blockers (e.g., ranitidine, famotidine) that have
less effect on CYP450. Cimetidine inhibits CYP2C9, CYP3A4, and CYP1A2, which are involved
in warfarin metabolism.
Question 2
A drug follows first-order elimination kinetics with a half-life of 6 hours. How long will it take to
reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 30 hours
D. 48 hours
ANsweR: C. 30 hours
,RAtioNAle: Steady-state is achieved after approximately 4-5 half-lives of drug administration.
With a half-life of 6 hours, 5 half-lives equals 30 hours (6 × 5 = 30). At this point, the rate of drug
administration equals the rate of elimination, and serum concentrations remain relatively
constant.
Question 3
A patient with chronic kidney disease (eGFR 25 mL/min/1.73m²) is prescribed a medication that
is primarily renally eliminated. The nurse practitioner should:
A. Prescribe the standard dose
B. Reduce the dose or increase the dosing interval
C. Increase the dose
D. Administer the medication IV only
ANsweR: B. Reduce the dose or increase the dosing interval
RAtioNAle: In patients with renal impairment, medications that are primarily renally eliminated
require dose reduction or extended dosing intervals to prevent drug accumulation and toxicity.
Creatinine clearance or eGFR should be used to guide dosing adjustments. Standard dosing (A)
would risk toxicity. Increasing the dose (C) would worsen toxicity.
Question 4
Which of the following factors would increase the volume of distribution (Vd) of a drug?
A. High protein binding
B. Low lipid solubility
C. High lipid solubility
D. Large molecular size
ANsweR: C. High lipid solubility
RAtioNAle: High lipid solubility increases the volume of distribution because lipophilic drugs
can readily cross cell membranes and distribute into adipose tissue and other compartments.
High protein binding (A) tends to decrease Vd by keeping the drug in the vascular space. Low
lipid solubility (B) and large molecular size (D) limit tissue distribution.
Question 5
The therapeutic index of a drug is defined as:
A. The ratio of the effective dose to the lethal dose
B. The ratio of the toxic dose to the therapeutic dose
C. The maximum effect a drug can produce
D. The dose required to produce a therapeutic effect in 50% of the population
ANsweR: B. The ratio of the toxic dose to the therapeutic dose
, RAtioNAle: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the therapeutic
dose (ED50). A narrow TI indicates a small margin between therapeutic and toxic doses,
requiring close monitoring (e.g., warfarin, digoxin, lithium). A wide TI indicates a larger safety
margin.
Question 6
A patient is prescribed a medication that is a CYP3A4 inducer. This medication will:
A. Decrease the metabolism of CYP3A4 substrates
B. Increase the metabolism of CYP3A4 substrates
C. Have no effect on CYP3A4 substrates
D. Increase the absorption of CYP3A4 substrates
ANsweR: B. Increase the metabolism of CYP3A4 substrates
RAtioNAle: CYP3A4 inducers increase the activity of the CYP3A4 enzyme, leading to
increased metabolism of drugs that are substrates for CYP3A4. This reduces serum
concentrations and therapeutic efficacy of those drugs. Examples include rifampin, phenytoin,
carbamazepine, and St. John's wort.
Question 7
Which of the following is a phase II metabolic reaction?
A. Oxidation
B. Reduction
C. Glucuronidation
D. Hydrolysis
ANsweR: C. Glucuronidation
RAtioNAle: Phase II metabolic reactions (conjugation reactions) involve attaching a polar
molecule (e.g., glucuronic acid, sulfate) to the drug to increase its water solubility and facilitate
excretion. Glucuronidation is a common phase II reaction. Oxidation (A), reduction (B), and
hydrolysis (D) are phase I reactions (functionalization reactions).
Question 8
The first-pass effect refers to:
A. The initial dose of a medication
B. The metabolism of a drug by the liver before it reaches systemic circulation
C. The binding of a drug to plasma proteins
D. The excretion of a drug by the kidneys
ANsweR: B. The metabolism of a drug by the liver before it reaches systemic circulation
– midteRm comPReheNsive exAmiNAtioN with veRiFied QuestioNs ANd coRRect
ANsweR RAtioNAles | | just ReleAsed .
This comprehensive practice examination covers the foundational principles of
pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacotherapeutics across
broad categories of agents used to treat common conditions encountered by the advanced
practice nurse. Topics include autonomic pharmacology, cardiovascular and renal
pharmacotherapy, endocrine agents, central nervous system medications, anti-infectives, and
special population considerations.
DOMAIN I: PHARMACOKINETICS, PHARMACODYNAMICS, AND PRESCRIBING
PRINCIPLES (Questions 1–25)
Question 1
A patient taking warfarin for atrial fibrillation is started on cimetidine for gastroesophageal reflux
disease. The nurse practitioner should anticipate which effect?
A. Decreased warfarin levels and increased INR
B. Increased warfarin levels and increased INR
C. Decreased warfarin levels and decreased INR
D. No change in warfarin levels or INR
ANsweR: B. Increased warfarin levels and increased INR
RAtioNAle: Cimetidine is a CYP450 inhibitor that inhibits the metabolism of warfarin, leading to
increased warfarin levels and increased INR. This increases the risk of bleeding. The NP should
monitor INR closely and consider alternative H2 blockers (e.g., ranitidine, famotidine) that have
less effect on CYP450. Cimetidine inhibits CYP2C9, CYP3A4, and CYP1A2, which are involved
in warfarin metabolism.
Question 2
A drug follows first-order elimination kinetics with a half-life of 6 hours. How long will it take to
reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 30 hours
D. 48 hours
ANsweR: C. 30 hours
,RAtioNAle: Steady-state is achieved after approximately 4-5 half-lives of drug administration.
With a half-life of 6 hours, 5 half-lives equals 30 hours (6 × 5 = 30). At this point, the rate of drug
administration equals the rate of elimination, and serum concentrations remain relatively
constant.
Question 3
A patient with chronic kidney disease (eGFR 25 mL/min/1.73m²) is prescribed a medication that
is primarily renally eliminated. The nurse practitioner should:
A. Prescribe the standard dose
B. Reduce the dose or increase the dosing interval
C. Increase the dose
D. Administer the medication IV only
ANsweR: B. Reduce the dose or increase the dosing interval
RAtioNAle: In patients with renal impairment, medications that are primarily renally eliminated
require dose reduction or extended dosing intervals to prevent drug accumulation and toxicity.
Creatinine clearance or eGFR should be used to guide dosing adjustments. Standard dosing (A)
would risk toxicity. Increasing the dose (C) would worsen toxicity.
Question 4
Which of the following factors would increase the volume of distribution (Vd) of a drug?
A. High protein binding
B. Low lipid solubility
C. High lipid solubility
D. Large molecular size
ANsweR: C. High lipid solubility
RAtioNAle: High lipid solubility increases the volume of distribution because lipophilic drugs
can readily cross cell membranes and distribute into adipose tissue and other compartments.
High protein binding (A) tends to decrease Vd by keeping the drug in the vascular space. Low
lipid solubility (B) and large molecular size (D) limit tissue distribution.
Question 5
The therapeutic index of a drug is defined as:
A. The ratio of the effective dose to the lethal dose
B. The ratio of the toxic dose to the therapeutic dose
C. The maximum effect a drug can produce
D. The dose required to produce a therapeutic effect in 50% of the population
ANsweR: B. The ratio of the toxic dose to the therapeutic dose
, RAtioNAle: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the therapeutic
dose (ED50). A narrow TI indicates a small margin between therapeutic and toxic doses,
requiring close monitoring (e.g., warfarin, digoxin, lithium). A wide TI indicates a larger safety
margin.
Question 6
A patient is prescribed a medication that is a CYP3A4 inducer. This medication will:
A. Decrease the metabolism of CYP3A4 substrates
B. Increase the metabolism of CYP3A4 substrates
C. Have no effect on CYP3A4 substrates
D. Increase the absorption of CYP3A4 substrates
ANsweR: B. Increase the metabolism of CYP3A4 substrates
RAtioNAle: CYP3A4 inducers increase the activity of the CYP3A4 enzyme, leading to
increased metabolism of drugs that are substrates for CYP3A4. This reduces serum
concentrations and therapeutic efficacy of those drugs. Examples include rifampin, phenytoin,
carbamazepine, and St. John's wort.
Question 7
Which of the following is a phase II metabolic reaction?
A. Oxidation
B. Reduction
C. Glucuronidation
D. Hydrolysis
ANsweR: C. Glucuronidation
RAtioNAle: Phase II metabolic reactions (conjugation reactions) involve attaching a polar
molecule (e.g., glucuronic acid, sulfate) to the drug to increase its water solubility and facilitate
excretion. Glucuronidation is a common phase II reaction. Oxidation (A), reduction (B), and
hydrolysis (D) are phase I reactions (functionalization reactions).
Question 8
The first-pass effect refers to:
A. The initial dose of a medication
B. The metabolism of a drug by the liver before it reaches systemic circulation
C. The binding of a drug to plasma proteins
D. The excretion of a drug by the kidneys
ANsweR: B. The metabolism of a drug by the liver before it reaches systemic circulation
